Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 14 | 2022 | 143 | 3.740 |
Why?
|
| Rhinitis | 7 | 2019 | 185 | 1.770 |
Why?
|
| Sinusitis | 7 | 2019 | 211 | 1.560 |
Why?
|
| Pandemics | 4 | 2022 | 274 | 1.520 |
Why?
|
| Betacoronavirus | 2 | 2020 | 89 | 1.270 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 101 | 1.210 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 104 | 1.200 |
Why?
|
| Allergens | 4 | 2019 | 22 | 1.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2022 | 149 | 1.100 |
Why?
|
| Allergists | 2 | 2023 | 2 | 1.090 |
Why?
|
| Prescriptions | 1 | 2023 | 18 | 0.890 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 20 | 0.840 |
Why?
|
| Nasal Polyps | 3 | 2019 | 71 | 0.780 |
Why?
|
| Drug Hypersensitivity | 2 | 2019 | 14 | 0.750 |
Why?
|
| Rhinitis, Allergic | 3 | 2018 | 27 | 0.750 |
Why?
|
| Influenza, Human | 1 | 2020 | 50 | 0.710 |
Why?
|
| Telemedicine | 1 | 2022 | 112 | 0.700 |
Why?
|
| Dyspnea | 1 | 2020 | 44 | 0.690 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 44 | 0.680 |
Why?
|
| Hypersensitivity | 1 | 2020 | 47 | 0.680 |
Why?
|
| Biological Therapy | 1 | 2019 | 5 | 0.670 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2019 | 5 | 0.670 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 5 | 0.670 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 115 | 0.630 |
Why?
|
| Penicillium | 2 | 2015 | 3 | 0.620 |
Why?
|
| Humans | 28 | 2023 | 31066 | 0.600 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 44 | 0.580 |
Why?
|
| Air Pollutants | 2 | 2014 | 13 | 0.570 |
Why?
|
| Electronic Health Records | 1 | 2017 | 72 | 0.570 |
Why?
|
| Poverty | 1 | 2017 | 97 | 0.560 |
Why?
|
| Residence Characteristics | 1 | 2017 | 226 | 0.530 |
Why?
|
| Patient Selection | 1 | 2017 | 246 | 0.520 |
Why?
|
| Eosinophilia | 2 | 2018 | 50 | 0.520 |
Why?
|
| Acer | 1 | 2015 | 1 | 0.500 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2015 | 6 | 0.500 |
Why?
|
| Vehicle Emissions | 1 | 2014 | 2 | 0.490 |
Why?
|
| Air Pollution | 1 | 2014 | 18 | 0.490 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2019 | 108 | 0.420 |
Why?
|
| Chronic Disease | 7 | 2019 | 534 | 0.420 |
Why?
|
| Male | 18 | 2020 | 16495 | 0.410 |
Why?
|
| Adult | 13 | 2020 | 8949 | 0.380 |
Why?
|
| Environmental Exposure | 1 | 2010 | 17 | 0.350 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2010 | 5 | 0.350 |
Why?
|
| Female | 16 | 2020 | 17016 | 0.340 |
Why?
|
| Skin Tests | 3 | 2015 | 13 | 0.340 |
Why?
|
| Alendronate | 2 | 2019 | 9 | 0.330 |
Why?
|
| Lung | 2 | 2020 | 173 | 0.320 |
Why?
|
| Breast Feeding | 1 | 2010 | 156 | 0.300 |
Why?
|
| Child, Preschool | 3 | 2015 | 691 | 0.290 |
Why?
|
| Income | 2 | 2017 | 80 | 0.290 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 66 | 0.280 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1133 | 0.260 |
Why?
|
| Parents | 2 | 2018 | 110 | 0.260 |
Why?
|
| Middle Aged | 11 | 2018 | 10238 | 0.230 |
Why?
|
| Causality | 1 | 2023 | 54 | 0.220 |
Why?
|
| Inhalation Exposure | 2 | 2014 | 6 | 0.210 |
Why?
|
| United States | 2 | 2019 | 2375 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 24 | 0.200 |
Why?
|
| Outpatients | 1 | 2021 | 57 | 0.190 |
Why?
|
| Aspirin | 2 | 2019 | 87 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 15 | 0.190 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2020 | 10 | 0.180 |
Why?
|
| Vaccination | 1 | 2020 | 48 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2015 | 1898 | 0.180 |
Why?
|
| Histamine Antagonists | 1 | 2020 | 5 | 0.180 |
Why?
|
| Sulfides | 1 | 2020 | 12 | 0.180 |
Why?
|
| Acetates | 1 | 2020 | 19 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 16 | 0.180 |
Why?
|
| Albuterol | 1 | 2020 | 15 | 0.180 |
Why?
|
| Cyclopropanes | 1 | 2020 | 25 | 0.180 |
Why?
|
| Risk | 1 | 2020 | 223 | 0.180 |
Why?
|
| Education, Distance | 1 | 2020 | 20 | 0.170 |
Why?
|
| Interleukin-5 | 1 | 2019 | 9 | 0.170 |
Why?
|
| Salmeterol Xinafoate | 1 | 2019 | 3 | 0.170 |
Why?
|
| Fluticasone | 1 | 2019 | 5 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 5 | 0.170 |
Why?
|
| Child | 3 | 2018 | 1431 | 0.160 |
Why?
|
| Phenotype | 2 | 2017 | 379 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 71 | 0.160 |
Why?
|
| Deprescriptions | 1 | 2018 | 1 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 105 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 109 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 387 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 42 | 0.150 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2018 | 7 | 0.150 |
Why?
|
| Aged | 5 | 2018 | 10078 | 0.150 |
Why?
|
| Health Information Exchange | 1 | 2017 | 6 | 0.150 |
Why?
|
| Chicago | 2 | 2018 | 943 | 0.150 |
Why?
|
| Polysomnography | 1 | 2018 | 99 | 0.150 |
Why?
|
| Observer Variation | 1 | 2017 | 118 | 0.150 |
Why?
|
| Nose | 1 | 2018 | 43 | 0.150 |
Why?
|
| Adolescent | 3 | 2018 | 2403 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 90 | 0.140 |
Why?
|
| Physicians | 1 | 2018 | 119 | 0.140 |
Why?
|
| Infant | 2 | 2015 | 578 | 0.130 |
Why?
|
| Cholecalciferol | 1 | 2016 | 7 | 0.130 |
Why?
|
| Decision Making | 1 | 2018 | 237 | 0.130 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2016 | 15 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 1209 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 34 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2018 | 3665 | 0.130 |
Why?
|
| Assertiveness | 1 | 2015 | 8 | 0.130 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2015 | 6 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2018 | 2045 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3809 | 0.120 |
Why?
|
| Alternaria | 1 | 2014 | 3 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 818 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2015 | 79 | 0.120 |
Why?
|
| Nasal Mucosa | 1 | 2015 | 17 | 0.120 |
Why?
|
| Disease Progression | 1 | 2017 | 829 | 0.120 |
Why?
|
| Eosinophils | 1 | 2015 | 49 | 0.120 |
Why?
|
| Young Adult | 2 | 2018 | 2063 | 0.120 |
Why?
|
| Pneumonia | 1 | 2015 | 75 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 420 | 0.120 |
Why?
|
| Hospitalization | 1 | 2016 | 336 | 0.110 |
Why?
|
| Risk Factors | 3 | 2017 | 2592 | 0.100 |
Why?
|
| Biomarkers | 1 | 2015 | 733 | 0.100 |
Why?
|
| Air Pollution, Indoor | 1 | 2010 | 3 | 0.090 |
Why?
|
| Dust | 1 | 2010 | 6 | 0.090 |
Why?
|
| Housing | 1 | 2010 | 16 | 0.090 |
Why?
|
| Food | 1 | 2010 | 32 | 0.090 |
Why?
|
| Trees | 1 | 2010 | 22 | 0.090 |
Why?
|
| Penicillins | 1 | 2009 | 11 | 0.080 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 27 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 5192 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2019 | 499 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2018 | 293 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 240 | 0.070 |
Why?
|
| Illinois | 2 | 2017 | 267 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2018 | 165 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 500 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2021 | 79 | 0.050 |
Why?
|
| Inpatients | 1 | 2021 | 150 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 17 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 14 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 42 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 23 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2018 | 36 | 0.040 |
Why?
|
| Patient Participation | 1 | 2018 | 53 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 443 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 360 | 0.030 |
Why?
|
| Microbiota | 1 | 2018 | 130 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 508 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 7 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 335 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 2015 | 12 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 874 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 74 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 168 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 718 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 123 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 453 | 0.030 |
Why?
|
| Self Care | 1 | 2015 | 91 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 408 | 0.030 |
Why?
|
| Intradermal Tests | 1 | 2009 | 1 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 36 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 244 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 148 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 510 | 0.020 |
Why?
|
| Animals | 1 | 2015 | 4719 | 0.020 |
Why?
|